Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

George F. Tidmarsh

Horizon Therapeutics Public Limited Company

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Metric
Company Name	Horizon Therapeutics Public Limited Company	Corcept Therapeutics Incorporated
Symbol	HZNP	CORT
MSH ID	COM:HORIZONTHERAPEUTICS	COM:CORCEPT
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Drug Manufacturers - General	Biotechnology
Country	IE	US
Stage
Employee Count	2.19K	352
Website	horizontherapeutics.com	corcept.com
LinkedIn
Founders

Metric
Market Cap		3.19B
Enterprise Value
Monthly Web Traffic		53.48K
Web Traffic Growth		3.98
Valuation
Raised Capital

Metric
Revenue	3.63B	482.38M
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.71B	475.89M
EBITDA	1.11B	109.64M
Operating Income	617.41M	107.28M
Net Income	521.48M	106.14M
EPS	2.28	1.02
Diluted EPS	2.22	0.94
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.75	0.99
Operating Profit Margin	0.14	0.23
EBITDA Margin	0.31	0.23
Net Profit Margin	0.12	0.23
Return on Equity	0.09	0.24
Return on Assets	0.05	0.18
Return on Capital Employed	0.06	0.22

COM:HORIZONTHERAPEUTICS

Horizon Therapeutics plc

Last Close

116.30

14/11 21:00

Volume Today

23.92M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	60.74	24.15
P/B Ratio	5.01	4.78
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	9.79	9.13
EV Multiple	38.99	41.21

Metric
Days Sales Outstanding	71.85	39.44
Days Payables Outstanding	34.56	1.00K
Days Inventory Outstanding	92.88	435.27
Operating Cycle	189.19	476.98
Cash Conversion Cycle	142.54	-212.43
Asset Turnover	0.39	0.80

Metric
Operating Cash Flow	1.26B	127.04M
Free Cash Flow	1.13B	126.90M
Cash Flow to Debt	0.41	1.64K
Operating Cash Flow/Sales	0.29	0.26
Free Cash Flow Yield	0.03	0.07

Metric
Cash & Equivalents	2.35B	135.55M
Accounts Receivable	-43.46M	-10.07M
Inventory	169.56M	7.73M
Goodwill	1.01B
Debt to Capitalization	0.33	0.01
Debt to Assets	0.28	0.00
Current Ratio	4.27	3.54
Quick Ratio	3.50	5.48

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.06	0.10
R&D to Revenue	0.14	0.37
SG&A to Revenue	0.21